Apollon Formularies (AQSE:APOL) Gross-Profit-to-Asset % : 2.52% (As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Apollon Formularies Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Apollon Formularies's annualized Gross Profit for the quarter that ended in Jun. 2023 was £0.10 Mil. Apollon Formularies's average Total Assets over the quarter that ended in Jun. 2023 was £3.81 Mil. Therefore, Apollon Formularies's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 was 2.52%.

Apollon Formularies Gross-Profit-to-Asset % Historical Data

The historical data trend for Apollon Formularies's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Gross-Profit-to-Asset % Chart

Apollon Formularies Annual Data

Trend

Jun10

Jun11

Dec12

Dec13

Dec14

Dec17

Dec18

Dec19

Dec20

Dec21

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

10.84

2.34

12.81

7.27

Apollon Formularies Semi-Annual Data
	Jun11	Jun12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Jun23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial											-	-	11.46	9.84	2.52

Competitive Comparison of Apollon Formularies's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollon Formularies's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's Gross-Profit-to-Asset % falls into.

Apollon Formularies Gross-Profit-to-Asset % Calculation

Apollon Formularies's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2021 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2021 )	/	( (Total Assets (A: Dec. 2020 )	+	Total Assets (A: Dec. 2021 ))	/ count )
	=	0.198	/	( (2.401	+	3.046)	/ 2 )
	=	0.198	/	2.7235
	=	7.27 %

Apollon Formularies's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2023 )	/	( (Total Assets (Q: Jun. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	0.096	/	( (3.658	+	3.957)	/ 2 )
	=	0.096	/	3.8075
	=	2.52 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Apollon Formularies Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollon Formularies (AQSE:APOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS

Website

https://www.apollon.org.uk

Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.